ticker nerd logo
Krystal Biotech Inc

Krystal Biotech Inc Stock Forecast & Price Prediction

Live Krystal Biotech Inc Stock (KRYS) Price
$111.77

4

Ratings

  • Buy 4
  • Hold 0
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$111.77

P/E Ratio

P/E Ratio not available for KRYS

Volume Traded Today

$255,449

Dividend

Dividends not available for KRYS

52 Week High/low

133.60/70.51

Krystal Biotech Inc Market Cap

$3.20B

🛑 Alert: These ten stocks could have higher potential than $KRYS 🛑

Before you buy KRYS you’ll want to see this list of ten stocks that have huge potential. Want to see if KRYS made the cut? Enter your email below

KRYS Summary

From what 4 stock analysts predict, the share price for Krystal Biotech Inc (KRYS) might increase by 47.18% in the next year. This is based on a 12-month average estimation for KRYS. Price targets go from $150.00 to $180.00. The majority of stock analysts believe KRYS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

KRYS Analyst Ratings

About 4 Wall Street analysts have assigned KRYS 4 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Krystal Biotech Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KRYS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

KRYS stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

KRYS Company Information

Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

KRYS
Krystal Biotech Inc (KRYS)

When did it IPO

2017

Staff Count

210

Country

United States

Sector/Industry

Healthcare/Biotechnology

CEO

Mr. Krish S. Krishnan M.B.A., M.S.

Market Cap

$3.20B

Krystal Biotech Inc(KRYS) Financial Data

In 2023, KRYS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KRYS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $8.6M
  • Operating Margin TTM -3.04%
  • Gross profit TTM $0
  • Return on assets TTM -0.12%
  • Return on equity TTM -0.05%
  • Profit margin 0%
  • Book value 26.81%
  • Market capitalisation $3.20B
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year -1.17
  • EPS next year N/A
... ...

Similar Stocks to Krystal Biotech Inc KRYS

🛑 Alert: These ten stocks could have higher potential than $KRYS 🛑

Before you buy KRYS you’ll want to see this list of ten stocks that have huge potential. Want to see if KRYS made the cut? Enter your email below

...

KRYS Frequently asked questions

The highest forecasted price for KRYS is $180.00 from joshua schimmer at Cantor Fitzgerald.

The lowest forecasted price for KRYS is $150.00 from dae gon ha from Stifel Nicolaus

The KRYS analyst ratings consensus are 4 buy ratings, 0 hold ratings, and 0 sell ratings.